Immunogenicity of a Canine Parvovirus 2 Capsid Antigen (VP2-S1) surface-expressed on Lactobacillus casei

다국어 초록 (Multilingual Abstract)

Canine parvovirus (CPV2) is one of the most virulent virus causing acute hemorrhagic enteritis and myocarditis in dogs. Infection mainly caused by the ingestion of virus through the mucosal route. Therefore, induction of mucosal immunity is essential in prevention of Canine Parvovirus (CPV2) infection. For safe and effective delivery of viral antigens to the mucosal immune system, a novel surface antigen display system for lactic acid bacteria using the poly-γ-glutamic acid synthetase A protein (pgsA) of Bacillus subtilis as an anchoring matrix was applied in order to display CPV2 antigen on the surface of the recombinant L. casei. Recombinant fusion proteins comprised of pgsA and the capsid protein (VP2-S1) showed stable expression in Lactobacillus casei. Surface localization of the fusion protein was verified by cellular fractionation analyses. Oral and nasal inoculations of recombinant L. casei into mice resulted in high levels of serum immunoglobulin G (IgG) and mucosal IgA, as demonstrated by ELISA using recombinant VP2-S1 proteins. Mice receiving intranasal immunization mounted higher antibody response than those receiving oral immunization. These results indicate that mucosal immunization with recombinant L. casei expressing CPV2 VP2-S1 protein on its surface provides an effective means for elicitation of strong antibody responses against CPV 2 VP2-S1.

참고문헌 (Reference)

1 Shata MT, "Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity" 75 : 9665-9670, 2001

2 Hénaut A, "Uneven distribution of GATC motifs in the Escherichia coli chromosome, its plasmids and its phages" 257 : 574-585, 1996

3 Tsao J, "The three-dimensional structure of canine parvovirus and its functional implications" 1251 : 1456-1464, 1991

4 Agbandje M, "The structure of parvoviruses" 6 : 299-309, 1995

5 Martella V, "Surveillance activity for canine parvovirus in Italy" 52 : 312-315, 2005

6 JS, "Surface-displayed viral antigens on Salmonella carrier vaccine" 18 : 645-648, 2000

7 Trieu-Cuot P, "Shuttle vectors containing a multiple cloning site and a lacZ alpha gene for conjugal transfer of DNA from Escherichia coli to gram-positive bacteria" 102 : 99-104, 1991

8 Blom N, "Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid Sequence" 4 : 1633-1649, 2004

9 Ashiuchi M, "Physiological and biochemical characteristics of poly gamma-glutamate synthetase complex of Bacillus subtilis" 268 : 5321-5328, 2001

10 Robinson K, "Oral vaccination of mice against tetanus with recombinant Lactococcus lactis" 15 : 653-657, 1997

11 Poo H, "Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice" 119 : 1702-1709, 2006

12 Decaro N, "Occurrence of severe gastroenteritis in pups after canine parvovirus vaccine administration: a clinical and laboratory diagnostic dilemma" 25 : 1161-1166, 2007

13 Mannam P, "Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes" 72 : 3444-3450, 2004

14 Lee JS, "Mucosal immunization with surface-displayed Severe Acute Respiratory Syndrome coronavirus spike protein in Lactobacillus casei induces neutralizing antibodies in mice" 80 : 4079-4087, 2006

15 Shata MT, "Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector" 20 : 623-629, 2001

16 Seegers JF, "Lactobacilli as live vaccine delivery vectors: progress and prospects" 20 : 508-515, 2002

17 Friedman RS, "Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens" 74 : 9987-9993, 2000

18 Langeveld JP, "Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus" 19 : 3661-3670, 2001

19 Kuwabara M, "Immunological effects of recombinant feline interferon-omega (KT-80) administration in the dog" 50 : 637-641, 2006

20 Xin KQ, "Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env" 102 : 223-228, 2003

21 Ventura M, "Identification and characterization of novel surface proteins in Lactobacillus johnsonii and Lactobacillus gasseri" 68 : 6172-6181, 2002

22 Langeveld JP, "First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs" 68 : 4506-4513, 1994

23 Decaro N, "First detection of canine parvovirus type 2c in pups with haemorrhagic enteritis in Spain" 53 : 468-472, 2006

24 López de Turiso JA, "Fine mapping of canine parvovirus B cell epitopes" 72 : 2445-2456, 1991

25 Truyen U, "Evolution of canine parvovirus--A need for new vaccines?" 117 : 9-13, 2006

26 Buonavoglia C, "Evidence for evolution of canine parvovirus type 2 in Italy" 82 : 3021-3025, 2001

27 Shaw DM, "Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli" 100 : 510-518, 2000

28 Parrish CR, "Antigenic relationships between canine parvovirus type 2, feline panleukopenia virus and mink enteritis virus using conventional antisera and monoclonal antibodies" 72 : 267-278, 1982

29 Leenhouts K, "Anchoring of proteins to lactic acid bacteria" 76 : 367-376, 1999

30 Nakamura M, "A novel antigenic variant of Canine parvovirus from a Vietnamese dog" 149 : 2261-2269, 2004